The new aspects of the eradication of Helicobacter pylori and the importance of bacterial resistance;A Helicobacter pylori eradikációjának legújabb szempontjai és a bakteriális rezisztencia jelentosége

Orvosi Hetilap

Volumn 149, Issue 43, 2008, Pages 2029-2035

  Hagymási, Krisztina ^a,b,c   Tulassay, Zsolt ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c Semmelweis Egyetem   (Hungary)

Author keywords

Bacterial resistance; Eradication; First and second line treatment; Helicobacter pylori; Sequential therapy; Treatment failure

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; FURAZOLIDONE; HERBACEOUS AGENT; LACTOFERRIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACOGENETICS; REVIEW;

EID: 56749150795     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28460     Document Type: Review

References (39)

1. Gastroenterologia. Szerk.: Varró V. Medicina. Könyvkiadó Rt., Budapest, 1998, 105-108.
2. Vakil, N., Megraud, F.: Eradication therapy for Helicobacter pylori. Gastroenterology, 2007, 133, 985-1001.
3. Mohammadi, M., Doroud, D., Mohajerani, N. és mtsa: Helicobacter pylori antibiotic resistance in Iran. W. J. Gastroenterol., 2005, 11, 6009-6013.
4. Wolle, K., Malfertheiner, P.: Treatment of Helicobacter pylori. Best Pract. Res. Clin. Gastroenterol., 2007, 21, 315-324.
5. Malfertheiner, P., Megraud, F., Morain, C, O. és mtsai, The European Helicobacter pylori Study Group (EHSG): Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56, 772-781.
6. Vakil, N., Lanza, F., Schwartz, H. és mtsa: Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther., 2004, 20, 99-107.
7. Zagari, R. M., Bianchi-Porro, G., Fiocca, R. és mtsai: Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut, 2007, 56, 475-479.
8. Prónai, L., Tulassay, Zs.: Failure of Helicobacter pylori eradication - suggestion for further therapy. Orv. Fletil., 2003, 144, 1299-1302.
9. Katelaris, P. H., Forbes, G. M., Talley, Y. J. és mtsa: A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology, 2002, 123, 1763-1769.
10. Rodríguez-Torres, M., Salgado Mercado, R., Ríos-Bedoya, C. F. és mtsai: High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig. Dis. Sci., 2005, 50, 634-639.
11. Gisbert, J. P., Gisbhert, J. L., Marcos, S. és mtsai: Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment. Pharmacol. Ther., 2005, 22, 1041-1046.
12. Furuta, T., Sugimoto, M., Shirai, N. és mtsai: Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment. Pharmacol. Ther., 2007, 26, 693-703.
13. Zambon, C. F., Basso, D., Navaglia, F. és mtsai: Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine, 2005, 29, 141-152.
14. Zambon, C. F., Fasolo, M., Basso, D. és mtsai: Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success. J. Gastrointest. Surg., 2007, 11, 1506-1514.
15. Camargo, M. C., Piazuelo, M. B., Mera, R. M. és mtsai: Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia. Acta Gastroenterol. Latinoam., 2007, 37, 238-245.
16. Abdullahi, M, Annibale, B., Capoccia, D. és mtsai: The eradication of Helicobacter pylori is Affected by Body Mass Index (BMI). Obes Surg., 2008 Apr 29. [Epub ahead of print]
17. Glupczynski, Y., Mégraud, F., Lopez-Brea, M. és mtsa: European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Ent. J. Clin. Microbiol. Infect. Dis., 2001, 20, 820-823.
18. Duck, W. M., Sobel, J., Pruckler, J. M. és mtsai: Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg. Infect. Dis., 2004, 10, 1088-1094.
19. De Francesco, V., Margiotta, M., Zullo, A. és mtsai: Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15-year period in Italy. J. Antimicrob. Chemother., 2007, 59, 783-785.
20. Mohammadi, M, Doroud, D., Mohajerani, N. és mtsa: Helicobacter pylori antibiotic resistance in Iran. W. J. Gastroenterol., 2005, 11, 6009-6013.
21. Furuta, T., Soya, Y., Sugimoto, M. és mtsai: Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J. Gastroenterol. Hepatol., 2007, 22, 1810-1815.
22. Matteo, M. J., Granados, G., Olmos, M. és mtsai: Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolates. J. Antimicrob. Chemother., 2008, 61, 474-477.
23. Gerrits, M. M., Berning, M., Van Vliet, A. H. és mtsai: Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob. Agents Chemother., 2003, 47, 2984-2986.
24. Glocker E., Bogdan, C., Kist, M.: Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. J. Antimicrob. Chemother., 2007, 59, 874-879.
25. Lee, C. C., Lee, V. W., Chan, F. K. és mtsa: Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy, 2008, 54, 50-53.
26. Han, F., Liu, S., Ho, B. és mtsai: Alterations in rdxA and frxA genes and their upstream regions in metronidazole-resistant Helicobacter pylori isolates. Res. Microbiol., 2007, 158, 38-44.
27. Zullo, A., De Francesco, V., Hassan, C. és mtsai: The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut, 2007, 56, 1353-1357.
28. Graham, D. Y., Lu, H., Yamaoka, Y.: Therapy for Helicobacter pylori infection can be improved. Sequential therapy and beyond. Drugs, 2008, 68, 725-736.
29. Gisbert, J. P., Pajares, R., Pajares, J. M.: Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter, 2007, 12 (Suppl. 2), 50-58.
30. Chey, W. D., Wong, B. C; Practice Parameters Committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol., 2007, 102, 1808-1825.
31. Gisbert, J. P., Bermejo, E, Castro-Fernández, M. és mtsai: Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am. J. Gastroenterol., 2008, 103, 71-76.
32. Van der Poorten, D., Katelaris, P. H.: The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment. Pharmacol. Ther., 2007, 26, 1537-1542.
33. Di Mario, F., Cavallaro, L. G., Scarpignato, C.: "Resue" therapies for the management of Helicobacter pylori infection. Dig. Dis., 2006, 24, 113-130.
34. Di Mario, F., Aragona, G., Dal Bó, N. és mtsai: Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment. Pharmacol. Ther., 2006, 23, 1235-1240.
35. Yamauchi, K., Wakabayashi, H., Shin, K. és mtsa: Bovine lactoferrin: benefits and mechanism of action against infections. Biochem. Cell Biol., 2006, 84, 291-296.
36. de Bortoli, N., Leonardi, G., Ciancia, E. és mtsai: Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am. J. Gastroenterol., 2007, 102, 951-956.
37. Gotteland, M., Brunser, O., Cruchet, S.: Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment. Pharmacol. Ther., 2006, 23, 1077-1086.
38. Nostro, A., Cellini, L., Di Bartolomeo, S. és mtsai: Antibacterial effect of plant extracts against Helicobacter pylori. Phytother. Res., 2005, 19, 198-202.
39. Moayyedi, P.: The health economics of Helicobacter pylori infection. Best Pract. Res. Clin. Gastroenterol., 2007, 21, 347-361.